6 results
The primary objective of this study is:• To evaluate the non-inferiority of switching to a TAF Containing STR relative to maintaining TDF Containing Regimens in Virologically Suppressed HIV-1 positive subjects as determined by having HIV 1 RNA * 50…
To determine the conversion rate of PR to CR (i.e. PET negativity) after a single dose of 90Y-ibritumomab tiuxetan (a dose of 14.8 MBq/kg or 0.4 mCi/kg, max 1184 MBq or 32mCi) in patients with grade 1-3a, stage II, III or IV follicular lymphoma with…
Primary Objectives:To determine the optimal dose of the VEGF-targeting optical agent Bevacizumab-IRDye800CW for an adequate tumor-tobackgroundratio (TBR) during white-light (WL) / fluorescence-guided (FG) diagnostic laparoscopy (WL/FG-DLS) in…
To determine the safety and feasibility of fluorescence imaging of the eye vascularization with the fluorescent tracer bevacizumab-800CW for identification of neovascular Age-related Macular Degeneration (AMD) with scanning laser angiography.
The main objective of this pilot study is to investigate the feasibility of fluorescence imaging with the fluorescence agent bevacizumab-800CW to detect endometriosis tissue.
Primary:To evaluate the performance of FME with topical administration of Bevacizumab-800CW for detection of neoplasia in BE patients compared to HD-WLE to make an estimation of the diagnostic accuracy in terms of sensitivity and specificity in…